51
|
Chiaradonna F, Cirulli C, Palorini R, Votta G, Alberghina L. New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer. Antioxid Redox Signal 2015; 23:30-50. [PMID: 24483782 DOI: 10.1089/ars.2014.5854] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
SIGNIFICANCE Histone deacetylases (HDACs) activity and cell metabolism are considered important targets for cancer therapy, as both are deregulated and associated with the onset and maintenance of tumors. RECENT ADVANCES Besides the classical function of HDACs as HDAC enzymes controlling the transcription, it is becoming increasingly evident that these proteins are involved in the regulation of several other cellular processes by their ability to deacetylate hundreds of proteins with different functions in both the cytoplasm and the nucleus. Importantly, recent high-throughput studies have identified as important target proteins several enzymes involved in different metabolic pathways. Conversely, it has been also shown that metabolic intermediates may control HDACs activity. Consequently, the acetylation/deacetylation of metabolic enzymes and the ability of metabolic intermediates to modulate HDACs may represent a cross-talk connecting cell metabolism, transcription, and other HDACs-controlled processes in physiological and pathological conditions. CRITICAL ISSUES Since metabolic alterations and HDACs deregulation are important cancer hallmarks, disclosing connections among them may improve our understanding on cancer mechanisms and reveal novel therapeutic protocols against this disease. FUTURE DIRECTIONS High-throughput metabolic studies performed by using more sophisticated technologies applied to the available models of conditional deletion of HDACs in cell lines or in mice will fill the gap in the current understanding and open directions for future research.
Collapse
Affiliation(s)
- Ferdinando Chiaradonna
- 1 SYSBIO Centre of Systems Biology , Milan, Italy .,2 Department of Biotechnology and Biosciences, University of Milano-Bicocca , Milan, Italy
| | - Claudia Cirulli
- 1 SYSBIO Centre of Systems Biology , Milan, Italy .,2 Department of Biotechnology and Biosciences, University of Milano-Bicocca , Milan, Italy
| | - Roberta Palorini
- 1 SYSBIO Centre of Systems Biology , Milan, Italy .,2 Department of Biotechnology and Biosciences, University of Milano-Bicocca , Milan, Italy
| | - Giuseppina Votta
- 1 SYSBIO Centre of Systems Biology , Milan, Italy .,2 Department of Biotechnology and Biosciences, University of Milano-Bicocca , Milan, Italy
| | - Lilia Alberghina
- 1 SYSBIO Centre of Systems Biology , Milan, Italy .,2 Department of Biotechnology and Biosciences, University of Milano-Bicocca , Milan, Italy
| |
Collapse
|
52
|
Ferguson BS, McKinsey TA. Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol 2015; 83:14-20. [PMID: 25791169 PMCID: PMC4459895 DOI: 10.1016/j.yjmcc.2015.03.010] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/22/2014] [Revised: 02/19/2015] [Accepted: 03/10/2015] [Indexed: 02/08/2023]
Abstract
Histone deacetylases (HDACs) catalyze the removal of acetyl-groups from lysine residues within nucelosomal histone tails and thousands of non-histone proteins. The 18 mammalian HDACs are grouped into four classes. Classes I, II and IV HDACs employ zinc as a co-factor for catalytic activity, while class III HDACs (also known as sirtuins) require NAD+ for enzymatic function. Small molecule inhibitors of zinc-dependent HDACs are efficacious in multiple pre-clinical models of pressure overload and ischemic cardiomyopathy, reducing pathological hypertrophy and fibrosis, and improving contractile function. Emerging data have revealed numerous mechanisms by which HDAC inhibitors benefit the heart, including suppression of oxidative stress and inflammation, inhibition of MAP kinase signaling, and enhancement of cardiac protein aggregate clearance and autophagic flux. Here, we summarize recent findings with zinc-dependent HDACs and HDAC inhibitors in the heart, focusing on newly described functions for distinct HDAC isoforms (e.g. HDAC2, HDAC3 and HDAC6). Potential for pharmacological HDAC inhibition as a means of treating age-related cardiac dysfunction is also discussed. This article is part of a Special Issue entitled: CV Aging.
Collapse
Affiliation(s)
- Bradley S Ferguson
- Department of Medicine, Division of Cardiology, University of Colorado, Denver, 12700 E. 19th Ave Aurora, CO 80045-0508, USA
| | - Timothy A McKinsey
- Department of Medicine, Division of Cardiology, University of Colorado, Denver, 12700 E. 19th Ave Aurora, CO 80045-0508, USA.
| |
Collapse
|
53
|
HDAC8: a multifaceted target for therapeutic interventions. Trends Pharmacol Sci 2015; 36:481-92. [PMID: 26013035 DOI: 10.1016/j.tips.2015.04.013] [Citation(s) in RCA: 174] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Revised: 04/27/2015] [Accepted: 04/28/2015] [Indexed: 02/08/2023]
Abstract
Histone deacetylase 8 (HDAC8) is a class I histone deacetylase implicated as a therapeutic target in various diseases, including cancer, X-linked intellectual disability, and parasitic infections. It is a structurally well-characterized enzyme that also deacetylates nonhistone proteins. In cancer, HDAC8 is a major 'epigenetic player' that is linked to deregulated expression or interaction with transcription factors critical to tumorigenesis. In the parasite Schistosoma mansoni and in viral infections, HDAC8 is a novel target to subdue infection. The current challenge remains in the development of potent selective inhibitors that would specifically target HDAC8 with fewer adverse effects compared with pan-HDAC inhibitors. Here, we review HDAC8 as a drug target and discuss inhibitors with respect to their structural features and therapeutic interventions.
Collapse
|
54
|
Cavasin MA, Stenmark KR, McKinsey TA. Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series). Pulm Circ 2015; 5:63-72. [PMID: 25992271 DOI: 10.1086/679700] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Accepted: 07/30/2014] [Indexed: 01/14/2023] Open
Abstract
Reversible lysine acetylation has emerged as a critical mechanism for controlling the function of nucleosomal histones as well as diverse nonhistone proteins. Acetyl groups are conjugated to lysine residues in proteins by histone acetyltransferases and removed by histone deacetylases (HDACs), which are also commonly referred to as lysine deacetylases. Over the past decade, many studies have shown that HDACs play crucial roles in the control of left ventricular (LV) cardiac remodeling in response to stress. Small molecule HDAC inhibitors block pathological hypertrophy and fibrosis and improve cardiac function in various preclinical models of LV failure. Only recently have HDACs been studied in the context of right ventricular (RV) failure, which commonly occurs in patients who experience pulmonary hypertension (PH). Here, we review recent findings with HDAC inhibitors in models of PH and RV remodeling, propose next steps for this newly uncovered area of research, and highlight potential for isoform-selective HDAC inhibitors for the treatment of PH and RV failure.
Collapse
Affiliation(s)
- Maria A Cavasin
- Department of Medicine, Division of Cardiology, University of Colorado Denver, Aurora, Colorado, USA
| | - Kurt R Stenmark
- Department of Pediatrics, Division of Pulmonary and Critical Care Medicine, University of Colorado Denver, Aurora, Colorado, USA
| | - Timothy A McKinsey
- Department of Medicine, Division of Cardiology, University of Colorado Denver, Aurora, Colorado, USA
| |
Collapse
|
55
|
Pietra F. Restoring Histone Deacetylase Activity by Waste Product Release. A View from Molecular Mechanics Simulations with Mammalian HDAC8. Chem Biodivers 2015; 12:503-12. [DOI: 10.1002/cbdv.201400314] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2014] [Indexed: 11/05/2022]
|
56
|
Decroos C, Clausen DJ, Haines BE, Wiest O, Williams RM, Christianson DW. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8. Biochemistry 2015; 54:2126-35. [PMID: 25793284 DOI: 10.1021/acs.biochem.5b00010] [Citation(s) in RCA: 48] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The macrocyclic depsipeptide Largazole is a potent inhibitor of metal-dependent histone deacetylases (HDACs), some of which are drug targets for cancer chemotherapy. Indeed, Largazole partially resembles Romidepsin (FK228), a macrocyclic depsipeptide already approved for clinical use. Each inhibitor contains a pendant side chain thiol that coordinates to the active site Zn(2+) ion, as observed in the X-ray crystal structure of the HDAC8-Largazole complex [Cole, K. E., Dowling, D. P., Boone, M. A., Phillips, A. J., and Christianson, D. W. (2011) J. Am. Chem. Soc. 133, 12474]. Here, we report the X-ray crystal structures of HDAC8 complexed with three synthetic analogues of Largazole in which the depsipeptide ester is replaced with a rigid amide linkage. In two of these analogues, a six-membered pyridine ring is also substituted (with two different orientations) for the five-membered thiazole ring in the macrocycle skeleton. The side chain thiol group of each analogue coordinates to the active site Zn(2+) ion with nearly ideal geometry, thereby preserving the hallmark structural feature of inhibition by Largazole. Surprisingly, in comparison with the binding of Largazole, these analogues trigger alternative conformational changes in loops L1 and L2 flanking the active site. However, despite these structural differences, inhibitory potency is generally comparable to, or just moderately less than, the inhibitory potency of Largazole. Thus, this study reveals important new structure-affinity relationships for the binding of macrocyclic inhibitors to HDAC8.
Collapse
Affiliation(s)
- Christophe Decroos
- †Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States
| | - Dane J Clausen
- ‡Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, United States
| | - Brandon E Haines
- §Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States
| | - Olaf Wiest
- §Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.,∥Laboratory of Computational Chemistry and Drug Design, Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China
| | - Robert M Williams
- ‡Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, United States.,⊥University of Colorado Cancer Center, Aurora, Colorado 80045, United States
| | - David W Christianson
- †Roy and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323, United States
| |
Collapse
|
57
|
Singh RK, Cho K, Padi SKR, Yu J, Haldar M, Mandal T, Yan C, Cook G, Guo B, Mallik S, Srivastava DK. Mechanism of N-Acylthiourea-mediated activation of human histone deacetylase 8 (HDAC8) at molecular and cellular levels. J Biol Chem 2015; 290:6607-19. [PMID: 25605725 DOI: 10.1074/jbc.m114.600627] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We reported previously that an N-acylthiourea derivative (TM-2-51) serves as a potent and isozyme-selective activator for human histone deacetylase 8 (HDAC8). To probe the molecular mechanism of the enzyme activation, we performed a detailed account of the steady-state kinetics, thermodynamics, molecular modeling, and cell biology studies. The steady-state kinetic data revealed that TM-2-51 binds to HDAC8 at two sites in a positive cooperative manner. Isothermal titration calorimetric and molecular modeling data conformed to the two-site binding model of the enzyme-activator complex. We evaluated the efficacy of TM-2-51 on SH-SY5Y and BE(2)-C neuroblastoma cells, wherein the HDAC8 expression has been correlated with cellular malignancy. Whereas TM-2-51 selectively induced cell growth inhibition and apoptosis in SH-SY5Y cells, it showed no such effects in BE(2)-C cells, and this discriminatory feature appears to be encoded in the p53 genotype of the above cells. Our mechanistic and cellular studies on HDAC8 activation have the potential to provide insight into the development of novel anticancer drugs.
Collapse
Affiliation(s)
| | | | | | - Junru Yu
- From the Departments of Chemistry and Biochemistry
| | | | | | - Changhui Yan
- Computer Science, North Dakota State University, Fargo, North Dakota 58108
| | - Gregory Cook
- From the Departments of Chemistry and Biochemistry
| | - Bin Guo
- Pharmaceutical Sciences, and
| | | | | |
Collapse
|
58
|
Kim B, Pithadia AS, Fierke CA. Kinetics and thermodynamics of metal-binding to histone deacetylase 8. Protein Sci 2015; 24:354-65. [PMID: 25516458 DOI: 10.1002/pro.2623] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 12/08/2014] [Indexed: 11/11/2022]
Abstract
Histone deacetylase 8 (HDAC8) was originally classified as a Zn(II)-dependent deacetylase on the basis of Zn(II)-dependent HDAC8 activity in vitro and illumination of a Zn(II) bound to the active site. However, in vitro measurements demonstrated that HDAC8 has higher activity with a bound Fe(II) than Zn(II), although Fe(II)-HDAC8 rapidly loses activity under aerobic conditions. These data suggest that in the cell HDAC8 could be activated by either Zn(II) or Fe(II). Here we detail the kinetics, thermodynamics, and selectivity of Zn(II) and Fe(II) binding to HDAC8. To this end, we have developed a fluorescence anisotropy assay using fluorescein-labeled suberoylanilide hydroxamic acid (fl-SAHA). fl-SAHA binds specifically to metal-bound HDAC8 with affinities comparable to SAHA. To measure the metal affinity of HDAC, metal binding was coupled to fl-SAHA and assayed from the observed change in anisotropy. The metal KD values for HDAC8 are significantly different, ranging from picomolar to micromolar for Zn(II) and Fe(II), respectively. Unexpectedly, the Fe(II) and Zn(II) dissociation rate constants from HDAC8 are comparable, koff ∼0.0006 s(-1), suggesting that the apparent association rate constant for Fe(II) is slow (∼3 × 10(3) M(-1) s(-1)). Furthermore, monovalent cations (K(+) or Na(+)) that bind to HDAC8 decrease the dissociation rate constant of Zn(II) by ≥100-fold for K(+) and ≥10-fold for Na(+), suggesting a possible mechanism for regulating metal exchange in vivo. The HDAC8 metal affinities are comparable to the readily exchangeable Zn(II) and Fe(II) concentrations in cells, consistent with either or both metal cofactors activating HDAC8.
Collapse
Affiliation(s)
- Byungchul Kim
- Chemical Biology Program, University of Michigan, Ann Arbor, Michigan, 48109-2216
| | | | | |
Collapse
|
59
|
Zheng XX, Zhou T, Wang XA, Tong XH, Ding JW. Histone deacetylases and atherosclerosis. Atherosclerosis 2014; 240:355-66. [PMID: 25875381 DOI: 10.1016/j.atherosclerosis.2014.12.048] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2014] [Revised: 12/17/2014] [Accepted: 12/18/2014] [Indexed: 01/13/2023]
Abstract
Atherosclerosis is the most common pathological process that leads to cardiovascular diseases, a disease of large- and medium-sized arteries that is characterized by a formation of atherosclerotic plaques consisting of necrotic cores, calcified regions, accumulated modified lipids, smooth muscle cells (SMCs), endothelial cells, leukocytes, and foam cells. Recently, the question about how to suppress the occurrence of atherosclerosis and alleviate the progress of cardiovascular disease becomes the hot topic. Accumulating evidence suggests that histone deacetylases(HDACs) play crucial roles in arteriosclerosis. This review summarizes the effect of HDACs and HDAC inhibitors(HDACi) on the progress of atherosclerosis.
Collapse
Affiliation(s)
- Xia-xia Zheng
- Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang 443000, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, Hubei Province, China
| | - Tian Zhou
- Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang 443000, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, Hubei Province, China
| | - Xin-An Wang
- Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang 443000, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, Hubei Province, China
| | - Xiao-hong Tong
- Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang 443000, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, Hubei Province, China
| | - Jia-wang Ding
- Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang 443000, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, Hubei Province, China.
| |
Collapse
|
60
|
Stratton MS, McKinsey TA. Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophy. Biochem Cell Biol 2014; 93:149-57. [PMID: 25707943 DOI: 10.1139/bcb-2014-0119] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Acetylation of lysine residues within nucleosomal histone tails provides a crucial mechanism for epigenetic control of gene expression. Acetyl groups are coupled to lysine residues by histone acetyltransferases (HATs) and removed by histone deacetylases (HDACs), which are also commonly referred to as "writers" and "erasers", respectively. In addition to altering the electrostatic properties of histones, lysine acetylation often creates docking sites for bromodomain-containing "reader" proteins. This review focuses on epigenetic control of pulmonary hypertension (PH) and associated right ventricular (RV) cardiac hypertrophy and failure. Effects of small molecule HDAC inhibitors in pre-clinical models of PH are highlighted. Furthermore, we describe the recently discovered role of bromodomain and extraterminal (BET) reader proteins in the control of cardiac hypertrophy, and provide evidence suggesting that one member of this family, BRD4, contributes to the pathogenesis of RV failure. Together, the data suggest intriguing potential for pharmacological epigenetic therapies for the treatment of PH and right-sided heart failure.
Collapse
Affiliation(s)
- Matthew S Stratton
- Department of Medicine, Division of Cardiology, University of Colorado Denver, 12700 E. 19th Ave, Aurora, CO 80045-0508, USA
| | | |
Collapse
|
61
|
Singh RK, Suzuki T, Mandal T, Balsubramanian N, Haldar M, Mueller DJ, Strode JA, Cook G, Mallik S, Srivastava DK. Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme. Biochemistry 2014; 53:7445-58. [PMID: 25407689 PMCID: PMC4263425 DOI: 10.1021/bi500711x] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
![]()
Among the different histone deacetylase
(HDAC) isozymes, HDAC8
is the most highly malleable enzyme, and it exhibits the potential
to accommodate structurally diverse ligands (albeit with moderate
binding affinities) in its active site pocket. To probe the molecular
basis of this feature, we performed detailed thermodynamic studies
of the binding of structurally similar ligands, which differed with
respect to the “cap”, “linker”, and “metal-binding”
regions of the suberoylanilide hydroxamic acid (SAHA) pharmacophore,
to HDAC8. The experimental data revealed that although the enthalpic
(ΔH°) and entropic (ΔS°) changes for the binding of individual SAHA analogues to HDAC8
were substantially different, their binding free energies (ΔG°) were markedly similar, conforming to a strong enthalpy–entropy
compensation effect. This effect was further observed in the temperature-dependent
thermodynamics of binding of all SAHA analogues to the enzyme. Notably,
in contrast to other metalloenzymes, our isothermal titration calorimetry
experiments (performed in different buffers of varying ionization
enthalpies) suggest that depending on the ligand, its zinc-binding
group may or may not be deprotonated upon the binding to HDAC8. Furthermore,
the heat capacity changes (ΔCp°) associated with the ligand binding
to HDAC8 markedly differed from one SAHA analogue to the other, and
such features could primarily be rationalized in light of the dynamic
flexibility in the enzyme structure in conjunction with the reorganization
of the active site resident water molecules. Arguments are presented
that although the binding thermodynamic features described above would
facilitate identification of weak to moderately tight-binding HDAC8
inhibitors (by a high-throughput and/or virtual screening of libraries
of small molecules), they would pose major challenges for the structure-based
rational design of highly potent and isozyme-selective inhibitors
of human HDAC8.
Collapse
Affiliation(s)
- Raushan K Singh
- Department of Chemistry and Biochemistry, North Dakota State University , Fargo, North Dakota 58102, United States
| | | | | | | | | | | | | | | | | | | |
Collapse
|
62
|
Olson D, Udeshi ND, Wolfson NA, Pitcairn CA, Sullivan ED, Jaffe JD, Svinkina T, Natoli T, Lu X, Paulk J, McCarren P, Wagner FF, Barker D, Howe E, Lazzaro F, Gale JP, Zhang YL, Subramanian A, Fierke CA, Carr SA, Holson EB. An unbiased approach to identify endogenous substrates of "histone" deacetylase 8. ACS Chem Biol 2014; 9:2210-6. [PMID: 25089360 PMCID: PMC4201337 DOI: 10.1021/cb500492r] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Accepted: 08/04/2014] [Indexed: 12/24/2022]
Abstract
Despite being extensively characterized structurally and biochemically, the functional role of histone deacetylase 8 (HDAC8) has remained largely obscure due in part to a lack of known cellular substrates. Herein, we describe an unbiased approach using chemical tools in conjunction with sophisticated proteomics methods to identify novel non-histone nuclear substrates of HDAC8, including the tumor suppressor ARID1A. These newly discovered substrates of HDAC8 are involved in diverse biological processes including mitosis, transcription, chromatin remodeling, and RNA splicing and may help guide therapeutic strategies that target the function of HDAC8.
Collapse
Affiliation(s)
- David
E. Olson
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Namrata D. Udeshi
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Noah A. Wolfson
- Department of Biological
Chemistry, Interdepartmental
Program in Chemical Biology, and Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Carol Ann Pitcairn
- Department of Biological
Chemistry, Interdepartmental
Program in Chemical Biology, and Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Eric D. Sullivan
- Department of Biological
Chemistry, Interdepartmental
Program in Chemical Biology, and Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Jacob D. Jaffe
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Tanya Svinkina
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Ted Natoli
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Xiaodong Lu
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Joshiawa Paulk
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Patrick McCarren
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Florence F. Wagner
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Doug Barker
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Eleanor Howe
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Fanny Lazzaro
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Jennifer P. Gale
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Yan-Ling Zhang
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Aravind Subramanian
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Carol A. Fierke
- Department of Biological
Chemistry, Interdepartmental
Program in Chemical Biology, and Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Steven A. Carr
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Edward B. Holson
- Stanley Center for Psychiatric Research, Proteomics Platform, Cancer Program, and Center for the
Science of Therapeutics, Broad Institute
of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
63
|
Decroos C, Bowman CM, Moser JAS, Christianson KE, Deardorff MA, Christianson DW. Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders. ACS Chem Biol 2014; 9:2157-64. [PMID: 25075551 PMCID: PMC4168803 DOI: 10.1021/cb5003762] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
![]()
Cornelia
de Lange Syndrome (CdLS) is a multiple congenital anomaly
disorder resulting from mutations in genes that encode the core components
of the cohesin complex, SMC1A, SMC3, and RAD21, or two of its regulatory
proteins, NIPBL and HDAC8. HDAC8 is the human SMC3 lysine deacetylase
required for cohesin recycling in the cell cycle. To date, 16 different
missense mutations in HDAC8 have recently been identified in children
diagnosed with CdLS. To understand the molecular effects of these
mutations in causing CdLS and overlapping phenotypes, we have fully
characterized the structure and function of five HDAC8 mutants: C153F,
A188T, I243N, T311M, and H334R. X-ray crystal structures reveal that
each mutation causes local structural changes that compromise catalysis
and/or thermostability. For example, the C153F mutation triggers conformational
changes that block acetate product release channels, resulting in
only 2% residual catalytic activity. In contrast, the H334R mutation
causes structural changes in a polypeptide loop distant from the active
site and results in 91% residual activity, but the thermostability
of this mutant is significantly compromised. Strikingly, the catalytic
activity of these mutants can be partially or fully rescued in vitro by the HDAC8 activator N-(phenylcarbamothioyl)benzamide.
These results suggest that HDAC8 activators might be useful leads
in the search for new therapeutic strategies in managing CdLS.
Collapse
Affiliation(s)
- Christophe Decroos
- Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323 United States
| | - Christine M. Bowman
- Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323 United States
| | - Joe-Ann S. Moser
- Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323 United States
| | - Karen E. Christianson
- Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323 United States
| | - Matthew A. Deardorff
- Division
of Human Genetics and Molecular Biology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States
- Department
of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
| | - David W. Christianson
- Roy
and Diana Vagelos Laboratories, Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6323 United States
| |
Collapse
|
64
|
Ha SD, Han CY, Reid C, Kim SO. HDAC8-mediated epigenetic reprogramming plays a key role in resistance to anthrax lethal toxin-induced pyroptosis in macrophages. THE JOURNAL OF IMMUNOLOGY 2014; 193:1333-43. [PMID: 24973453 DOI: 10.4049/jimmunol.1400420] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Macrophages pre-exposed to a sublethal dose of anthrax lethal toxin (LeTx) are refractory to subsequent high cytolytic doses of LeTx, termed toxin-induced resistance (TIR). A small population of TIR cells (2-4%) retains TIR characteristics for up to 5-6 wk. Through studying these long-term TIR cells, we found that a high level of histone deacetylase (HDAC)8 expression was crucial for TIR. Knocking down or inhibition of HDAC8 by small interfering RNAs or the HDAC8-specific inhibitor PCI-34051, respectively, induced expression of the mitochondrial death genes Bcl2 adenovirus E1B 19 kDa-interacting protein 3 (BNIP3), BNIP3-like and metastatic lymph node 64, and resensitized TIR cells to LeTx. Among multiple histone acetylations, histone H3 lysine 27 (H3K27) acetylation was most significantly decreased in TIR cells in an HDAC8-dependent manner, and the association of H3K27 acetylation with the genomic regions of BNIP3 and metastatic lymph node 64, where HDAC8 was recruited to, was diminished in TIR cells. Furthermore, overexpression of HDAC8 or knocking down the histone acetyltransferase CREB-binding protein/p300, known to target H3K27, rendered wild-type cells resistant to LeTx. As in RAW264.7 cells, primary bone marrow-derived macrophages exposed to a sublethal dose of LeTx were resistant to LeTx in an HDAC8-dependent manner. Collectively, this study demonstrates that epigenetic reprogramming mediated by HDAC8 plays a key role in determining the susceptibility of LeTx-induced pyroptosis in macrophages.
Collapse
Affiliation(s)
- Soon-Duck Ha
- Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6G 2V4, Canada
| | - Chae Young Han
- Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6G 2V4, Canada
| | - Chantelle Reid
- Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6G 2V4, Canada
| | - Sung Ouk Kim
- Department of Microbiology and Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario N6G 2V4, Canada
| |
Collapse
|
65
|
Moser MA, Hagelkruys A, Seiser C. Transcription and beyond: the role of mammalian class I lysine deacetylases. Chromosoma 2014; 123:67-78. [PMID: 24170248 PMCID: PMC3967066 DOI: 10.1007/s00412-013-0441-x] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2013] [Revised: 10/07/2013] [Accepted: 10/14/2013] [Indexed: 11/25/2022]
Abstract
The Rpd3-like members of the class I lysine deacetylase family are important regulators of chromatin structure and gene expression and have pivotal functions in the control of proliferation, differentiation and development. The highly related class I deacetylases HDAC1 and HDAC2 have partially overlapping but also isoform-specific roles in diverse biological processes, whereas HDAC3 and HDAC8 have unique functions. This review describes the role of class I KDACs in the regulation of transcription as well as their non-transcriptional functions, in particular their contributions to splicing, mitosis/meiosis, replication and DNA repair. During the past years, a number of mouse loss-of-function studies provided new insights into the individual roles of class I deacetylases in cell cycle control, differentiation and tumorigenesis. Simultaneous ablation of HDAC1 and HDAC2 or single deletion of Hdac3 severely impairs cell cycle progression in all proliferating cell types indicating that these class I deacetylases are promising targets for small molecule inhibitors as anti-tumor drugs.
Collapse
Affiliation(s)
- Mirjam Andrea Moser
- Department of Medical Biochemistry, Max F. Perutz Laboratories, Medical University of Vienna, Dr. Bohr-Gasse 9/2, 1030 Vienna, Austria
| | - Astrid Hagelkruys
- Department of Medical Biochemistry, Max F. Perutz Laboratories, Medical University of Vienna, Dr. Bohr-Gasse 9/2, 1030 Vienna, Austria
| | - Christian Seiser
- Department of Medical Biochemistry, Max F. Perutz Laboratories, Medical University of Vienna, Dr. Bohr-Gasse 9/2, 1030 Vienna, Austria
| |
Collapse
|
66
|
Lötsch J, Schneider G, Reker D, Parnham MJ, Schneider P, Geisslinger G, Doehring A. Common non-epigenetic drugs as epigenetic modulators. Trends Mol Med 2013; 19:742-53. [PMID: 24054876 DOI: 10.1016/j.molmed.2013.08.006] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2013] [Revised: 08/16/2013] [Accepted: 08/19/2013] [Indexed: 12/15/2022]
Abstract
Epigenetic effects are exerted by a variety of factors and evidence increases that common drugs such as opioids, cannabinoids, valproic acid, or cytostatics may induce alterations in DNA methylation patterns or histone conformations. These effects occur via chemical structural interactions with epigenetic enzymes, through interactions with DNA repair mechanisms. Computational predictions indicate that one-twentieth of all drugs might potentially interact with human histone deacetylase, which was prospectively experimentally verified for the compound with the highest predicted interaction probability. These epigenetic effects add to wanted and unwanted drug effects, contributing to mechanisms of drug resistance or disease-related and unrelated phenotypes. Because epigenetic changes might be transmitted to offspring, the need for reliable and cost-effective epigenetic screening tools becomes acute.
Collapse
Affiliation(s)
- Jörn Lötsch
- Institute of Clinical Pharmacology, Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany; Fraunhofer Institute of Molecular Biology and Applied Ecology - Project Group Translational Medicine and Pharmacology (IME-TMP), Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.
| | | | | | | | | | | | | |
Collapse
|
67
|
Olson DE, Wagner FF, Kaya T, Gale JP, Aidoud N, Davoine EL, Lazzaro F, Weïwer M, Zhang YL, Holson EB. Discovery of the first histone deacetylase 6/8 dual inhibitors. J Med Chem 2013; 56:4816-20. [PMID: 23672185 DOI: 10.1021/jm400390r] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
We disclose the first small molecule histone deacetylase (HDAC) inhibitor (3, BRD73954) capable of potently and selectively inhibiting both HDAC6 and HDAC8 despite the fact that these isoforms belong to distinct phylogenetic classes within the HDAC family of enzymes. Our data demonstrate that meta substituents of phenyl hydroxamic acids are readily accommodated upon binding to HDAC6 and, furthermore, are necessary for the potent inhibition of HDAC8.
Collapse
Affiliation(s)
- David E Olson
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|